文献速递肝病

利巴韦林稳态血浆水平可预测接受直接抗病毒药物治疗的丙型肝炎感染患者的持续病毒学应答

Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
PubMed 文献 · Aliment Pharmacol Ther · 2017-09-07

在荷兰四家学术医疗中心连续纳入183例接受直接抗病毒药物联合利巴韦林治疗的丙型肝炎病毒感染患者,于治疗第8周前瞻性检测利巴韦林稳态血浆水平。多变量分析显示较高的利巴韦林稳态血浆水平是持续病毒学应答的独立预测因素(调整OR 1.79,95%CI 1.09-2.93),163例(89%)获得持续病毒学应答。

要点

  • 利巴韦林稳态血浆水平较高是接受直接抗病毒药物联合利巴韦林治疗患者获得持续病毒学应答的独立预测因素(调整OR 1.79,95%CI 1.09-2.93)。
  • 获得持续病毒学应答的利巴韦林稳态血浆水平最佳下限截止值为2.28 mg/L,预防显著贫血(血红蛋白<10 g/dL)的上限截止值为3.61 mg/L。
  • 183例患者中85%具有一项或以上难治特征(经治、HCV基因3型、肝硬化),163例(89%)获得持续病毒学应答。

核心结论

  • 在主要为难治患者的接受直接抗病毒药物联合利巴韦林治疗队列中,较高的利巴韦林稳态血浆水平是持续病毒学应答的独立预测因素。

研究设计与样本

  • 前瞻性连续纳入荷兰四家学术医疗中心接受直接抗病毒药物联合利巴韦林治疗的丙型肝炎病毒感染患者,共183例,于治疗第8周采用经验证的检测方法测定利巴韦林稳态血浆水平,并进行逻辑回归分析和ROC曲线下面积分析。

主要发现

  • 183例患者中85%具有一项或以上难治特征(即经治、HCV基因3型、肝硬化),多数接受以索磷布韦为基础的治疗方案,163例(89%)获得持续病毒学应答。
  • 利巴韦林中位剂量为12.9 mg/kg/d(四分位距11.2-14.7),利巴韦林稳态血浆水平中位数为2.66 mg/L(四分位距1.95-3.60)。
  • 多变量分析中,较高的利巴韦林稳态血浆水平是持续病毒学应答的独立预测因素(调整OR 1.79,95%CI 1.09-2.93)。
  • 关于最佳利巴韦林治疗范围,2.28 mg/L为获得持续病毒学应答的最佳下限截止值,3.61 mg/L为预防显著贫血(血红蛋白<10 g/dL)的上限截止值。

关键数值与推荐

  • 利巴韦林稳态血浆水平较高是持续病毒学应答的独立预测因素(调整OR 1.79,95%CI 1.09-2.93)。
  • 获得持续病毒学应答的利巴韦林稳态血浆水平最佳下限截止值为2.28 mg/L。
  • 预防显著贫血(血红蛋白<10 g/dL)的利巴韦林稳态血浆水平上限截止值为3.61 mg/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the era of highly effective direct-acting antivirals (DAAs) for treatment of patients with chronic hepatitis C virus (HCV) infection, ribavirin (RBV) is still considered beneficial in certain patients. AIM: To assess the association between RBV steady-state plasma levels and sustained virological response (SVR). METHODS: Consecutive HCV-infected patients treated with DAAs plus RBV from four Dutch academic medical centres were enrolled. RBV steady-state plasma levels were prospectively measured at treatment week 8 using validated assays. Logistic regression analyses were performed to assess the influence of RBV steady-state plasma level on SVR, and RBV therapeutic range was explored using area under the ROC curve analyses. RESULTS: A total of 183 patients were included, of whom 85% had one or more difficult-to-cure characteristics (ie treatment experienced, HCV genotype 3, cirrhosis). The majority was treated with a sofosbuvir-based regimen and 163 (89%) patients achieved SVR. Median RBV dose was 12.9 (interquartile range 11.2-14.7) mg/kg/d, and median RBV steady-state plasma level was 2.66 (1.95-3.60) mg/L. In multivariable analyses, higher RBV steady-state plasma level (adjusted odds ratio 1.79 [95% CI 1.09-2.93]) was an independent predictor of SVR. With regard to the optimal RBV therapeutic range, 2.28 mg/L was the optimal lower cut-off for achieving SVR and 3.61 mg/L was the upper cut-off for preventing significant anaemia (Haemoglobin < 10 g/dL). CONCLUSION: In this cohort of mainly difficult-to-cure patients treated with DAAs plus RBV, higher RBV steady-state plasma level was an independent predictor of SVR.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. van Tilborg M, Lieveld FI, Smolders EJ, et al. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. Aliment Pharmacol Ther. 2017. PMID: 28881031. doi:10.1111/apt.14288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。